Frankfurt - Delayed Quote EUR

Esperion Therapeutics, Inc. (0ET.F)

0.6780

-0.1400

(-17.11%)

As of 3:57:39 PM GMT+2. Market Open.

Esperion to Participate in Upcoming June Investor Conferences

ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Espe

GlobeNewswire 3 days ago

ESPR
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to th

GlobeNewswire 11 days ago

ESPR
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines

HLS is tasked with receiving approval for these medicines from Health Canada, which is anticipated by the end of this year.

Pharmaceutical Technology 14 days ago

ESPR
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90

GlobeNewswire 14 days ago

ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement materia

GlobeNewswire 14 days ago

ESPR
HLS Therapeutics Announces Q1 2025 Financial Results

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended March 31, 2025. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

CNW Group 15 days ago

ESPR

HLTRF
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into an agreement with Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) to in-license and commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada. All financial figures are in U.S. dollars unless otherwise stated.

CNW Group 15 days ago

ESPR

HLTRF
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusiv

GlobeNewswire 15 days ago

ESPR
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.

Zacks 16 days ago

ESPR
Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Esperion Therapeutics Inc (ESPR) reports a 63% revenue increase, driven by strong US sales and strategic pipeline developments.

GuruFocus.com 16 days ago

ESPR
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -16.67% and 12.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 17 days ago

ESPR
Esperion Therapeutics: Q1 Earnings Snapshot

ANN ARBOR, Mich. AP) — Esperion Therapeutics Inc. ESPR) on Tuesday reported a loss of $40.5 million in its first quarter.

Associated Press Finance 17 days ago

ESPR
Esperion Reports First Quarter 2025 Financial Results

– Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes – – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Confere

GlobeNewswire 17 days ago

ESPR
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 22 days ago

COLL

ESPR
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 24 days ago

ESPR

OCUL
Esperion to Participate in The Citizens Life Sciences Conference

ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Thera

GlobeNewswire 28 days ago

ESPR
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.

Zacks 29 days ago

AUPH

HRTX

ESPR
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:

GlobeNewswire 29 days ago

ESPR
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

Zacks 30 days ago

PSTV

HRTX

AUPH
Esperion to Report First Quarter 2025 Financial Results on May 6

ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours afte

GlobeNewswire 30 days ago

ESPR

Performance Overview

Return	0ET.F	S&P 500 (^GSPC)
YTD	-65.94%	-1.34%
1-Year	-66.98%	+10.15%
3-Year	-88.53%	+46.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Esperion Therapeutics, Inc. (0ET.F)

Esperion to Participate in Upcoming June Investor Conferences

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

HLS Therapeutics Announces Q1 2025 Financial Results

HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Reports First Quarter 2025 Financial Results

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion to Participate in The Citizens Life Sciences Conference

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Esperion to Report First Quarter 2025 Financial Results on May 6

Performance Overview